Regulatory reform and investment in innovation have supercharged China’s biopharma sector, but will ongoing trade wars with the US pose a risk to growth? By Diana Turner. China’s role in the global biopharma sector has grown significantly in recent years. It is the world's largest supplier of active pharmaceutical ingredients (APIs) and in 2021, the country was reported […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!